DE60226431D1 - Pyrrolidinesterderivate mit oxytocinmodulierender wirkung - Google Patents

Pyrrolidinesterderivate mit oxytocinmodulierender wirkung

Info

Publication number
DE60226431D1
DE60226431D1 DE60226431T DE60226431T DE60226431D1 DE 60226431 D1 DE60226431 D1 DE 60226431D1 DE 60226431 T DE60226431 T DE 60226431T DE 60226431 T DE60226431 T DE 60226431T DE 60226431 D1 DE60226431 D1 DE 60226431D1
Authority
DE
Germany
Prior art keywords
aryl
alkyl
heteroaryl
group
pyrrolidine esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60226431T
Other languages
English (en)
Inventor
Matthias Schwarz
Anna Quattropani
Alexander Scheer
Jerome Dorbais
Vincent Pomel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Laboratoires Serono SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Serono SA filed Critical Laboratoires Serono SA
Application granted granted Critical
Publication of DE60226431D1 publication Critical patent/DE60226431D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
DE60226431T 2001-03-20 2002-03-19 Pyrrolidinesterderivate mit oxytocinmodulierender wirkung Expired - Lifetime DE60226431D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106888 2001-03-20
PCT/EP2002/003005 WO2002074741A1 (en) 2001-03-20 2002-03-19 Pyrrolidine ester derivatives with oxytocin modulating acitvity

Publications (1)

Publication Number Publication Date
DE60226431D1 true DE60226431D1 (de) 2008-06-19

Family

ID=8176843

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60226431T Expired - Lifetime DE60226431D1 (de) 2001-03-20 2002-03-19 Pyrrolidinesterderivate mit oxytocinmodulierender wirkung

Country Status (10)

Country Link
US (2) US7189754B2 (de)
EP (2) EP1390347B1 (de)
JP (1) JP4350948B2 (de)
AT (1) ATE394371T1 (de)
AU (1) AU2002256685B2 (de)
CA (1) CA2440002A1 (de)
DE (1) DE60226431D1 (de)
ES (1) ES2303854T3 (de)
IL (1) IL157995A0 (de)
WO (1) WO2002074741A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1390347B1 (de) * 2001-03-20 2008-05-07 Laboratoires Serono SA Pyrrolidinesterderivate mit oxytocinmodulierender wirkung
HUP0400238A2 (hu) * 2001-06-18 2004-07-28 Applied Research Systems Ars Holding N.V. Pirrolidin-oxadiazol- és tiadiazolszármazékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények
ATE449067T1 (de) * 2003-02-27 2009-12-15 Merck Serono Sa Pyrrolidin-derivate als oxytocin antagonisten
JP5539717B2 (ja) * 2006-07-14 2014-07-02 塩野義製薬株式会社 オキシム化合物およびその使用
US8563732B2 (en) 2007-05-31 2013-10-22 Shionogi & Co., Ltd. Oxyimino compounds and the use thereof
JP2010540584A (ja) * 2007-10-01 2010-12-24 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ受容体アンタゴニストとしてのｎ−複素環ビアリールカルボキサミド類
ES2408159T3 (es) 2008-06-11 2013-06-18 Shionogi & Co., Ltd. Compuestos de oxicarbamoilo y su utilización
EP2845850A1 (de) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidinderivate als Oxytocin/Vasopressin-V1a-Rezeptorantagonisten
EP2886107A1 (de) 2013-12-17 2015-06-24 ObsEva S.A. Orale Formulierungen von Pyrrolydinderivaten
CN114105851A (zh) 2014-07-02 2022-03-01 奥布赛瓦股份公司 治疗ot-r活性相关的病症的方法中可用的晶体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5481005A (en) * 1990-07-31 1996-01-02 Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5521173A (en) * 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
AU4763896A (en) 1995-01-24 1996-08-14 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5756497A (en) 1996-03-01 1998-05-26 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
EP0977209B8 (de) 1998-02-13 2006-11-15 The Furukawa Electric Co., Ltd. Isolierter draht
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
EP1390347B1 (de) 2001-03-20 2008-05-07 Laboratoires Serono SA Pyrrolidinesterderivate mit oxytocinmodulierender wirkung

Also Published As

Publication number Publication date
IL157995A0 (en) 2004-03-28
US20040147511A1 (en) 2004-07-29
EP1829861A3 (de) 2009-01-21
AU2002256685B2 (en) 2008-01-24
EP1390347B1 (de) 2008-05-07
EP1829861A2 (de) 2007-09-05
WO2002074741A1 (en) 2002-09-26
ATE394371T1 (de) 2008-05-15
US7189754B2 (en) 2007-03-13
ES2303854T3 (es) 2008-09-01
CA2440002A1 (en) 2002-09-26
JP4350948B2 (ja) 2009-10-28
US20070129381A1 (en) 2007-06-07
JP2004525132A (ja) 2004-08-19
EP1390347A1 (de) 2004-02-25

Similar Documents

Publication Publication Date Title
ATE427300T1 (de) Heterocyclisch substituierte amide als calpainhemmer
AR041816A1 (es) Compuesto de acil-pirrolidina, su uso para preparar una composicion farmaceutica, composicion farmaceutica que lo comprende y procedimiento para prepararlo
ATE405840T1 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
SE0301446D0 (sv) New Compounds
ATE383339T1 (de) Amin-derivate zur behandlung von apoptosis
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
EA200500304A1 (ru) Производные 3-(сульфонамидоэтил)индола, предназначенные для использования в качестве миметиков глюкокортикоидов при лечении воспалительных, аллергических и пролиферативных заболеваний
ATE497963T1 (de) Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen
ATE382598T1 (de) Flüssigkristallverbindungen
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
DE60233884D1 (de) 4(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidon-derivate als pde-4-hemmer zur behandlung von neurologischen syndromen
DE60226431D1 (de) Pyrrolidinesterderivate mit oxytocinmodulierender wirkung
NO20050740L (no) Ny fremgangsmate for syntesen av (7-metoksy-1-naftyl)acetonitril og anvendelse i syntesen av agomelatin
UY26820A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
SE0403171D0 (sv) New compounds
DE602004011255D1 (de) Phosphinsäurederivate, inhibitoren von beta-sekretase zur behandlung von alzheimer-krankheit
ATE271390T1 (de) Verwendung von azithromycin zur topischen behandlung von augeninfektionen
BR8900834A (pt) 1,2,4-triazinodionas substituidas e processo para sua preparacao;compostos intermediarios para as mesmas e processos para sua preparacao;composicoes contra protozoarios parasitarios;processo para o combate dos mesmos;e processo para preparacao de composicoes contra protozoarios parasitarios
ES2115904T3 (es) Derivados amino ramificados del tiazol, sus procedimientos de preparacion y las composiciones farmaceuticas que los contienen.
ATE538796T1 (de) Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit
DE58902739D1 (de) Verwendung von acylierten aminosaeureester-derivaten zur insekten- und milbenabwehr.
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE361755T1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition